Art

J-GLOBAL ID：202202288287689130   Reference number：22A2057926

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

転移性去勢抵抗性前立腺癌(mCRPC)に対する現在および新たな治療【JST・京大機械翻訳】

Author (7)： Henriquez Ivan (Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain) ,  III Mack Roach (UCSF Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology, San Francisco, CA 94143, USA) ,  Morgan Todd M. (Rogel Cancer Center, Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA) ,  Bossi Alberto (Prostate Brachytherapy Unit, Department of Radiation Oncology, Genito Urinary Oncology, Goustave Roussy, 94805 Paris, France) ,  Gomez Junior A. (Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain) ,  Abuchaibe Oscar (Virgilio Galvis Ramirez Cancer Centre, Department of Radiation Oncology, Bucaramanga 681004, Colombia) ,  Counago Felipe (Department of Radiation Oncology, Clinical Department, Faculty of Biomedicine, Hospital Universitario Quironsalud Madrid, Hospital La Luz, Universidad Europea, 28223 Madrid, Spain)
Material： Biomedicines (Web)
Volume： 9  Issue： 9  Page： 1247  Publication year： 2021 
JST Material Number： U7146A  ISSN： 2227-9059  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Metastatic castration-resistan...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A2057926&from=J-GLOBAL&jstjournalNo=U7146A") }}

Thesaurus term： tumor ,  *therapy ,  *prostatic tumor
Semi thesaurus term： 臨床医 , 【Automatic Indexing@JST】

Author keywords (4)： mCRPC ,  prostate cancer ,  androgen deprivation therapy ,  novel therapies

JST classification (2)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (53)：

• Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 145-164.
• El Cáncer en Cifras-SEOM: Sociedad Española de Oncología Médica © 2019 [Internet]. [Citado 23 de Diciembre de 2020]. Available online: https://seom.org/prensa/el-cancer-en-cifras (accessed on 17 December 2020).
• Valero, J.; Peleteiro, P.; Henriquez, I.; Conde, A.; Piquer, T.; Lozano, A.; Soler, C.C.; Muñoz, J.; Llescas, A.; Jove, J.; et al. Age, Gleason and PSA are important prognostic factors for survival in metastático castration-resistant prostate cancer. Results of the Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clin. Transl. Oncol. 2020, 22, 1378-1389.
• Scher, H.I.; Solo, K.; Valant, J.; Todd, M.B.; Mehra, M. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 2015, 10, e0139440.
• Scher, H.I.; Morris, M.J.; Stadler, W.M.; Higano, C.; Basch, E.; Fizazi, K.; Antonarakis, E.S.; Beer, T.M.; Carducci, M.A.; Chi, K.N.; et al. Trial Design and Objectives for Castration-. Prostate Cancer: Updated Recommendations from the Prostate cancer Clinical Trials Working Group 3. J. Clin. Oncol. 2016, 34, 1402-1418.

Terms in the title (3)： 転移性去勢抵抗性前立腺癌 ,  mCRPC ,  治療